|Bid||11.72 x 800|
|Ask||13.47 x 800|
|Day's Range||11.33 - 11.93|
|52 Week Range||8.29 - 26.01|
|Beta (3Y Monthly)||2.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.40|
NEW YORK, Feb. 11, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Rachel King has been the CEO of GlycoMimetics, Inc. (NASDAQ:GLYC) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
GlycoMimetics, Inc. (GLYC) shared at the 60th American Society of Hematology (ASH) Annual Meeting yesterday two posters with preclinical data presentations: on GMI-1687, the company’s highly potent E-selectin antagonist that is bioavailable via subcutaneous administration, and GMI-1757, the company’s dual-function E-selectin/galectin-3 antagonist. “The new preclinical data presented at ASH underscore GlycoMimetics’ commitment to pioneering advances in the field of glycobiology and to rationally designing innovative drug candidates that address areas of significant unmet medical need,” said John Magnani, Ph.D., Senior Vice President and Chief Scientific Officer.
ROCKVILLE, Md.-- -- Data in relapsed/refractory and newly diagnosed acute myeloid leukemia patients underscore clinical opportunities across multiple outcomes measures and subgroups Selective disruption of bone marrow microenvironment with uproleselan resulting in high remission rates; majority of evaluable patients achieving stringent level of measurable residual disease negativity; promising survival ...
GlycoMimetics, Inc. (GLYC) announced today that it will host and webcast an investor/analyst meeting and update at the 60th American Society of Hematology (ASH) Annual Meeting in San Diego, on December 3 at 6 a.m. PT. Daniel J. DeAngelo, MD, PhD, Director of Clinical and Translational Research, Adult Leukemia Program, Dana-Farber Cancer Institute/Brigham and Women’s Hospital, Associate Professor of Medicine, Harvard Medical School, who served as lead investigator of the GlycoMimetics’ recently completed Phase 1/2 clinical trial of uproleselan in acute myeloid leukemia patients, will recap and provide perspective on his December 2 oral presentation at the ASH meeting, highlighting the trial’s findings. GlycoMimetics management will review additional posters from the ASH meeting.
GlycoMimetics, Inc. (GLYC) today announced that it has appointed Scott Jackson, former Chief Executive Officer of Celator Pharmaceuticals, Inc., to its Board of Directors. Mr. Jackson served as Celator’s CEO and as a member of its Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Mr. Jackson has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. He holds a B.S. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. Mr. Jackson presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society.
GlycoMimetics, Inc. (GLYC) announced today dosing of the first patient in the company’s Phase 3 clinical trial of uproleselan (GMI-1271) in relapsed/refractory AML. The company anticipates the initiation of two complementary Phase 2/3 trials from two leading clinical consortia in early 2019.
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 27 cents. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
ROCKVILLE, Md.-- -- Continued to select new clinical sites and ready previously-selected sites in the U.S., Europe, Canada and Australia for the company-sponsored Phase 3 pivotal trial in relapsed/refractory AML; study now open for enrollment Received notice of Japanese patent issuance in August for uproleselan composition of matter as well as pharmaceutical formulations, expiring in December 2032 ...
ROCKVILLE, Md.-- -- New and updated clinical outcomes data and subgroup analyses continue to demonstrate potential benefit of treatment with uproleselan when added to chemotherapy 69 percent of evaluable patients with relapsed/refractory acute myeloid leukemia and 56 percent of evaluable patients with newly diagnosed AML achieved MRD-negative remission in clinical trial Correlation of E-selectin ligand ...
GlycoMimetics, Inc. (GLYC) announced today that it will host a conference call and webcast to provide a corporate update and report its third-quarter 2018 financial results on Friday, November 2, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at two upcoming investor conferences, as follows:
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
GlycoMimetics, Inc. (GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly issued patent covers uproleselan’s composition of matter as well as pharmaceutical formulations, and expires in December 2032. “The JPO’s issuance of a patent for uproleselan extends major market intellectual property coverage for this E-selectin antagonist drug candidate,” stated Rachel King, GlycoMimetics’ Chief Executive Officer.
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 8:30 AM Eastern Time. ...
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 26 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
ROCKVILLE, Md.-- -- Announced a Cooperative Research and Development Agreement to collaborate with the National Cancer Institute and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan in older, newly diagnosed acute myeloid leukemia patients eligible for intensive chemotherapy Continued to select new clinical sites and ready previously-selected ...
GlycoMimetics, Inc. (GLYC) announced today that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.